novartis_rm_logo_pos_rgb.png
cosentyx logo r.jpeg
LEAP logo options.png

LEAP Into the Real World:

A review of the latest real-world evidence for Cosentyx® (secukinumab) from the EuroSpA collaboration

 
Thursday 30 June 2022 | 18:00 BST

LEAP logo options.png
Spot_Light_Background.png

This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Limited and is intended for UK healthcare professionals only.

UK | June 2022 | 215175

By clicking the below link (www.mhra.gov.uk/yellowcard) you will leave the Novartis-associated website. This link will take you to a website to which our privacy policy does not apply.

You are solely responsible for your interactions with that website.

Adverse events should be reported. Reporting forms and information can be found at  www.mhra.gov.uk/yellowcard (UK).

Adverse events should also be reported to Novartis via  uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at  www.report.novartis.com

If you have a question about a product, please contact Medical Information on 01276 698370 or by email at  medinfo.uk@novartis.com

To learn about your data privacy rights and the use of your personal information, we invite you to read our General Privacy Notice for Business Partners.

Cosentyx (secukinumab) is indicated for: Adult patients with active psoriatic arthritis, alone or in combination with methotrexate, where response to previous disease-modifying anti-rheumatic drugs has been inadequate; Adult patients with active ankylosing spondylitis with an inadequate response to conventional therapy; Adult patients with non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by CRP and/or MRI evidence, where response to non-steroidal anti-inflammatory drugs has been inadequate.